Active Stocks
Fri Jun 14 2024 15:58:47
  1. HDFC Bank share price
  2. 1,597.45 1.05%
  1. State Bank Of India share price
  2. 840.20 -0.44%
  1. Tata Steel share price
  2. 183.05 0.30%
  1. ICICI Bank share price
  2. 1,105.10 -0.20%
  1. Kotak Mahindra Bank share price
  2. 1,717.00 -0.54%
Business News/Market/Market Stats/    Nippon India Pharma Fund - Growth

Nippon India Pharma Fund - Growth

+
  • Equity
  • Sector - Healthcare
  • Rating N.A.
  • Plan
451.87 +1.91 (0.42%) NAV as on 13 Jun, 2024
  • 5D
  • 1M
  • 6M
  • 1Y
  • 5Y
  • MAX

Key Metrics

  • AUM (in Cr)7160.93
  • CAGR 52.49%
  • Exit Load1.00%
  • Expense ratio1.82%
  • CategoryEquity
  • Min Investment5000
  • Min SIP100
  • Launch Date2004-06-05

Morning Star Rating N.A.

Medium
Risk
Exceptional
Return

Asset Allocation

Holdings As On - 14 June 2024

  • Name
  • Value (Cr)
  • Holding %
View More

Risk & Volitility

  • Alpha 5.93%
  • Beta 0.89
  • Sharpe Ratio0.60
  • Std Deviation 14.36%
  • Tracking Error 5.26%

About Fund

The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.

 

The Nippon India Pharma Fund - Growth has an AUM of 7160.93 crores & has delivered CAGR of 25.97% in the last 5 years. The fund has an exit load of 1.00% and an expense ratio of 1.82%. The minimum investment in Nippon India Pharma Fund - Growth is Rs 5000 and the minimum SIP is Rs 100.

 

As per morningstar the risk & return rating of the fund are Medium & Exceptional respectively.

 

The top holdings of the fund include Sun Pharmaceutical Industries, Lupin, Divis Laboratories & Cipla.

 

The major sectors where the fund is invested are Biotechnology & Drugs, Healthcare Facilities, Major Drugs & Retail (Drugs).

 

Some of the similar funds are ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Growth, DSP Healthcare Fund Regular Growth, SBI Healthcare Opportunities Fund Regular Growth, Nippon India Pharma Fund - Growth, Mirae Asset Healthcare Fund Regular Growth. Nippon India Pharma Fund - Growth has a sharpe ratio of 0.60 & a standard deviation of 14.36%.

FAQs about Nippon India Pharma Fund - Growth

According to the morning star rating Nippon India Pharma Fund - Growth has a Medium risk & Exceptional return.
Nippon India Pharma Fund - Growth is managed by Sailesh Raj Bhan,Kinjal Desai.
The expense ratio of Nippon India Pharma Fund - Growth is 1.82%.
The 5 year annualized return on Nippon India Pharma Fund - Growth is 25.97% & it has generated 52.49% in the last 1 year.
The minimum investment in Nippon India Pharma Fund - Growth is 5000 Rs.
Nippon India Pharma Fund - Growth has an AUM of 7160.93 crores.
Recommended For You